Abstract
Chronic infection with hepatitis C virus (HCV) is a major problem for thalassaemia patients, as blood transfusions before 1990 were associated with a high risk of HCV infection [...]
Highlights
1990 were associated with a high risk of hepatitis C virus (HCV) infection
Given the buvir with velpatasvir and voxilaprevir were lular carcinoma
Lenging in the interferon-alfa (IFN) era due to its According to all international current guidelines, thalassaemia unfavourable safety and tolerability profile but due to necessary patients do not represent a special group for the current HCV treatcombined use of ribavirin (RBV) and the subsequent haemolysis and increased need for blood transfusions
Summary
1990 were associated with a high risk of HCV infection. Given the buvir with velpatasvir and voxilaprevir (nucleotide analogue high prevalence of co-morbidities, thalassaemia patients are at an NS5B polymerase inhibitor/NS5A inhibitor/ NS3/4 protease increased risk for dying from end-stage liver disease or hepatocel- inhibitor, one tablet of 400/100/100 mg once daily) were lular carcinoma. George Papatheodoridis Professor in Medicine and Gastroenterology, Medical School of National and Kapodistrian University of Athens , Director of Academic Department of Gastroenterology, Laiko General Hospital, Athens, Greece
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
